C12N 2710/16041
Use of virus, viral particle or viral elements as a vector
C12N2710/16041 (Use of virus, viral particle or viral elements as a vector) appears on 62 US grants and 75 published applications in this corpus.
Search patents in C12N- Granted patents
- 62
- Published applications
- 75
- Assignees
- 54
- Inventors
- 153
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 1 |
| 2002 | 3 | 3 |
| 2003 | 2 | 1 |
| 2004 | 0 | 3 |
| 2005 | 1 | 1 |
| 2006 | 3 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 2 | 2 |
| 2010 | 1 | 2 |
| 2011 | 1 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 2 | 1 |
| 2016 | 1 | 4 |
| 2017 | 6 | 6 |
| 2018 | 1 | 2 |
| 2019 | 4 | 5 |
| 2020 | 5 | 5 |
| 2021 | 2 | 5 |
| 2022 | 3 | 6 |
| 2023 | 2 | 5 |
| 2024 | 2 | 6 |
| 2025 | 1 | 3 |
| 2026 | 6 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16043Viral genome or elements thereof as genetic vectorIndexing code58
- C12N 2710/16044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code2
- C12N 2710/16042Virus or viral particle as vehicleIndexing code1
- C12N 2710/16045Special targeting system for viral vectorsIndexing code1
Recent patents
- Compositions and methods for the treatment of skin diseases16 Jun 2026US 12,655,447 B2Krystal Biotech, Inc.
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Compositions and methods for delivering CFTR polypeptides13 Jan 2026US 12,522,636 B2Krystal Biotech, Inc.
- Vaccines for treating SARS infections in cancer patients6 Jan 2026US 12,516,296 B2City of Hope
- Methods and systems for manufacturing viral vectors6 Jan 2026US 12,516,349 B2Regeneron Pharmaceuticals, Inc.
- Therapeutic base editing30 Jul 2026US 2026/0216245 A1The J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst
- Adeno-Associated Virus Production Platform9 Jul 2026US 2026/0193676 A1MedImmune, LLC
- Compositions and Methods for Delivering CFTR Polypeptides30 Apr 2026US 2026/0116934 A1Krystal Biotech, Inc.
- Modified Herpes Simplex Virus Type 16 Nov 2025US 2025/0340903 A1Eg 427
- Larygotracheitis Virus (LT) Vector Vaccines for use with Avian Respiratory Pathogens25 Sep 2025US 2025/0295753 A1Edge Animal Health, Inc.
Most cited
By later US patents
- Porcine circoviruses vaccines diagnostic reagents105US 6,391,314 B1Merial Limited · 2002
- Porcine circoviruses, vaccines and diagnostic reagents77US 6,660,272 B2Merial Limited · 2003
- Porcine circoviruses, vaccines and diagnostic reagents58US 7,122,192 B2Merial Limited · 2006
- Recombinant adeno-associated vectors for targeted treatment36US 9,777,291 B2City of Hope · 2017
- Recombinant adeno-associated vectors for targeted treatment36US 9,783,825 B2City of Hope · 2017